С-reactive protein in the diagnostics of communicative pneumonia

Cover Page

Cite item

Full Text

Abstract

The article provides an analysis of current information about the diagnostic value of the C-reactive protein in therapy and pulmonology in the context of the differential search for pathology of the respiratory system organs, as well as nosological forms that have common elements of clinical symptoms characteristic of community-acquired pneumonia. The history of discovery, main effects, biological significance and features of laboratory diagnosis of C-reactive protein content in blood are reflected. The results of studies on the use of C-reactive protein concentration as a biological marker of the occurrence of community-acquired pneumonia, its complications and severity, as well as the adequacy of the selected antibacterial therapy are critically disclosed.

About the authors

Anton V. Ershov

I.M.Sechenov First Moscow State Medical University (Sechenov University); Federal Research and Clinical Center for Resuscitation and Rehabilitation

Email: salavatprof@mail.ru
D. Sci. (Med.), Prof., Senior Res. Officer, V.A.Negovsky Institute of General Reanimatology Moscow, Russia

References

  1. Титова О.Н., Кузубова Н.А., Лебедева Е.С. Биомаркеры прогноза тяжести течения и исхода внебольничной пневмонии. Мед. альянс. 2018; 2: 55-60.
  2. Бородулин Б.Е., Черногаева Г.Ю., Бородулина Е.А. и др. Летальность от внебольничной пневмонии в условиях многопрофильной больницы за 10 лет. Мед. альманах. 2012; 2 (21): 34-6.
  3. Бородулина Е.А., Бородулин Б.Е., Поваляева Л.В. и др. Предикторы летальности от внебольничной пневмонии в современных условиях работы пульмонологического центра. Вестн. современ. клин. медицины. 2015; 8 (4): 19-22.
  4. Чучалин А.Г., Синопальников А.И., Козлов Р.С. и др. Внебольничная пневмония у взрослых: практические рекомендации по диагностике, лечению и профилактике. М.: МАКМАХ, 2010.
  5. Muller B, Harbarth S, Stolz D et al. Diagnostic and prognostic accuracy of clinical and laboratory parameters in community-acquired pneumonia. BMC Infect Dis 2007; 7: 10.
  6. Watkins R.R, Lemonovich T.L. Diagnosis and management of community-acquired pneumonia in adult. Am Fam Physician 2011; 83 (11): 1299-306.
  7. Woodhead M et al. ERS/ESCMID Joint Task Force. Clin Microbiol Infect 2011; 17 (6): 1.
  8. Бобылев А.А., Рачина С.А., Авдеев С.Н., Дехнич Н.Н. Клиническое значение определения С-реактивного белка в диагностике внебольничной пневмонии. Клин. фармакология и терапия. 2016; 25 (2): 32-42.
  9. Бобылев А.А., Рачина С.А., Авдеев С.Н., Младов В.В. Перспективы применения биомаркеров для диагностики внебольничной пневмонии на фоне хронической сердечной недостаточности. Клин. фармакология и терапия. 2018; 27 (3): 16-25.
  10. Tillet W, Francis T. Serological reaction in pneumonia with a non-protein somatic fraction of Pneumococcus. J Exp Med 1930; 52: 561-71.
  11. Ghose T. Oswald Avery: the professor, DNA, and the Nobel Prize that eluded him. Can Bull Med Hist 2004; 21 (1): 135-44.
  12. Bottazzi B, Doni A, Garlanda C, Mantovani A. An integrated view of humoral innate immunity: pentraxins as a paradigm. Ann Rev Immunol 2010; 28: 157-83.
  13. MacLeod C.M, Avery O.T. The occurrence during acute infections of a protein not normally present in the blood: II. Isolation and properties of the reactive protein. J Exp Med 1941; 73 (2): 183-90.
  14. Singh P.P, Voleti B, Agrawal A. A novel RBP-J kappa-dependent switch from C/EBP beta to C/EBP zeta at the C/EBP binding site on the C-reactive protein promoter. J Immunol 2007; 178 (11): 7302-9.
  15. Thompson D, Pepys M.B, Wood S.P. The physiological structure of human Creactive protein and its complex with phosphocholine. Structure 1999; 7 (2): 169-77.
  16. Рыдловская А.В., Симбирцев А.С. Функциональный полиморфизм гена TNF-a и патология. Цитокины и воспаление. 2005; 4 (3): 4-10.
  17. Shaddock E.J. How and when to use common biomarkers in community-acquired pneumonia. Pneumonia (Nathan) 2016; 8: 17.
  18. Young B, Greeson M, Gripps A.W et al. C-reactive protein: a critical review. Pathology 1991; 23: 118-24.
  19. Зайцев А.А., Кондратьева Т.В., Маджанова Е.Р. Диагностические и прогностические возможности количественного определения С-реактивного белка при внебольничной пневмонии. Воен.-мед. журн. 2013; 11: 35-40.
  20. Pepys M.B, Hirschfield G.M. C-reactive protein: a critical update. J Clin Invest 2003; 111: 1805-12.
  21. Yuste J et al. Serum amyloid P aids complement-mediated immunity to Streptococcus pneumonia. PLoS Pathog 2007; 3 (9): 1208-19.
  22. Brown J.S et al. The classical pathway is the dominant complement pathway required for innate immunity to Streptococcus pneumoniae infection in mice. Proc Natl Acad Sci U S A 2002; 99 (26): 16969-74.
  23. Kerr A.R et al. Innate immune defense against pneumococcal pneumonia requires pulmonary complement component C3. Infect Immun 2005; 73 (7): 4245-52.
  24. Li Y.P, Mold C, Du Clos T.W. Sublytic complement attack exposes C-reactive protein binding sites on cell membranes. J Immunol 1994; 152 (6): 2995-3005.
  25. Bauer S, Lamy O. Role of C-reactive protein in the diagnosis, prognosis and follow-up of community-acquired pneumonia. Rev Med Suisse 2010; 6 (269): 2068-70.
  26. Van der Meer V, Neven A, Van den Broek P, Assendelft W. Diagnostic value of C reactive protein in infections of the lower respiratory tract: systematic review. BMJ 2005; 331 (7507): 26.
  27. Flanders S.A, Stein J, Shochat G et al. Performance of a bedside C-reactive protein test in the diagnosis of community-acquired pneumonia in adults with acute cough. Am J Med 2004; 116: 529-35.
  28. Kang Y.A, Kwon S.Y, Yoon H.I et al. Role of C-reactive protein and procalcitonin in differentiation of tuberculosis from bacterial community acquired pneumonia. Korean J Intern Med 2009; 24 (4): 337-42.
  29. Steurer J, Held U, Spaar A et al. A decision aid to rule out pneumonia and reduce unnecessary prescriptions of antibiotics inprimary care patients with cough and fever. BMC Med 2011; 9: 56.
  30. Almirall J, Bolipar I, Vidal J et al. Contribution of C-reactive protein to the diagnosis and assessment of severity of community-acquired pneumonia. Chest 2004; 125: 1335-42.
  31. Bafadhel M, Clark T.W, Reid C et al. Procalcitonin and C-reactive protein in hospitalized adult patients with communityacquired pneumonia or exacerbation of asthma or COPD. Chest 2011; 139 (6): 1410-8.
  32. Авдеев С.Н., Баймаканова Г.Е., Зубаирова П.А. Возможности С-реактивного белка в диагностике бактериальной инфекции и пневмонии у больных с обострением хронической обструктивной болезни легких. Уральский мед. журн. 2008; 13: 19-24.
  33. Garcia Vazquez E, Martines J.A, Menza J et al. C-reactive protein levels in community-acquired pneumonia. Eur Respir J 2003; 21: 702-5.
  34. Hohenthal U, Hurme S, Helenius H et al. Utility of C-reactive protein in assessing the disease severity and complications of community-acquired pneumonia. Clin Microbiol Infect 2009; 15 (11): 1026-32.
  35. Chalmers J.D, Singanayagam A, Scally C et al. Risk Factors for complicated parapneumonic effusion and empyema on presentation to hospital with community-acquired pneumonia. Thorax 2009; 64: 592-597.
  36. Menendez R, Martinez R, Reyes S et al. Stability in community-acquired pneumonia: one step forward with markers? Thorax 2009; 64: 987-92.
  37. Smith R.P. C-reactive protein in simple community-acquired pneumonia. Chest 1995; 107: 1028-31.
  38. Bruns A.H, Oosterheert J.J, Hak E, Hoepelman A.I. Usefulness of consecutive C-reactive protein measurements in follow-up of severe community-acquired pneumonia. Eur Respir J 2008; 32: 726-32.
  39. Seligman R, Ramos-Lima L.F, Oliveira V.A et al. Biomarkers in community-acquired pneumonia: A state-of-the-art review. Clinics 2012; 67 (11): 1321-5.
  40. Castro-Guardiola A, Armengou-Arxe A, Viedjo-Rodriguez A et al. Differential diagnosis between community-acquired pneumonia and non-pneumonia diseases of the chest in the emergency ward. Eur J Intern Med 2000; 11: 334-9.
  41. Вахитов Х.М., Пикуза О.И., Вахитова Л.Ф. и др. Значение определения С-реактивного белка для дифференциальной диагностики бронхита и пневмонии у детей. Практ. медицина. 2012; 7 (63): 23.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2019 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Согласие на обработку персональных данных

 

Используя сайт https://journals.rcsi.science, я (далее – «Пользователь» или «Субъект персональных данных») даю согласие на обработку персональных данных на этом сайте (текст Согласия) и на обработку персональных данных с помощью сервиса «Яндекс.Метрика» (текст Согласия).